LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (LBRX)
CUSIP: 50180M108
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 25,386,253
- Total 13F shares
- 19,945,854
- Share change
- +19,945,854
- Total reported value
- $314,944,399
- Price per share
- $15.79
- Number of holders
- 53
- Value change
- +$314,944,399
- Number of buys
- 53
Quarterly Holders Quick Answers
What is CUSIP 50180M108?
CUSIP 50180M108 identifies LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2025
Recent filing periods for CUSIP 50180M108:
Top shareholders of LBRX - LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Marc L. Panoff |
3/4/5
|
Senior Vice President, Finance |
—
mixed-class rows
|
100,767
mixed-class rows
|
$177,187 | — | 10 Sep 2025 | |
| Deep Track Capital, LP |
13D/G
|
— |
15%
|
3,352,804
|
— | $0 | 12 Sep 2025 | |
| TCG Crossover GP II, LLC |
13D/G
|
— |
7.8%
|
1,745,015
|
— | $0 | 12 Sep 2025 | |
| Ran Nussbaum |
3/4/5
|
Director |
—
mixed-class rows
|
1,434,130
mixed-class rows
|
— | — | 12 Sep 2025 | |
| Pontifax Management 4 G.P. (2015) Ltd. |
3/4/5
13D/G
|
10%+ Owner |
6.3%
from 13D/G
|
1,411,681
|
— | — | 12 Sep 2025 | |
| Commodore Capital LP |
13D/G
|
— |
5.5%
|
1,225,000
|
— | $0 | 11 Sep 2025 | |
| Heather D. Turner |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
971,828
|
— | — | 10 Sep 2025 | |
| Vida Ventures GP III, L.L.C. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
883,677
|
— | — | 12 Sep 2025 | |
| Deep Track Special Opportunities Fund, LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
666,666
|
— | — | 12 Sep 2025 | |
| Gad Soffer |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
229,860
|
— | — | 10 Sep 2025 | |
| Anna Eramo |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
159,397
mixed-class rows
|
— | — | 10 Sep 2025 | |
| Zachary Prensky |
3/4/5
|
Director |
—
mixed-class rows
|
83,723
mixed-class rows
|
— | — | 10 Sep 2025 | |
| Richard Anthony Silva |
3/4/5
|
SVP, Technical Operations |
—
class O/S missing
|
80,899
|
— | — | 10 Sep 2025 | |
| Robert R. Ruffolo |
3/4/5
|
Director |
—
mixed-class rows
|
24,814
mixed-class rows
|
— | — | 10 Sep 2025 | |
| J. Scott Garland |
3/4/5
|
Director |
—
class O/S missing
|
22,449
|
— | — | 10 Sep 2025 | |
| Rebecca Luse |
3/4/5
|
Director |
—
class O/S missing
|
22,449
|
— | — | 10 Sep 2025 | |
| Rekha Hemrajani |
3/4/5
|
Director |
—
class O/S missing
|
22,449
|
— | — | 10 Sep 2025 | |
| William P. Kane Jr. |
3/4/5
|
Director |
—
class O/S missing
|
22,449
|
— | — | 10 Sep 2025 |
Institutional Holders of LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (LBRX) as of Q3 2025
As of 30 Sep 2025,
LB PHARMACEUTICALS INC - Common Stock, $0.0001 par value per share (LBRX) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,945,854 shares.
The largest 10 holders included
Deep Track Capital, LP, RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, Commodore Capital LP, Logos Global Management LP, JPMORGAN CHASE & CO, BlackRock, Inc., Balyasny Asset Management L.P., Vivo Capital, LLC, and JENNISON ASSOCIATES LLC.
This page lists
53
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q4 2025 Across Filers
Q4 2025 holders
67
Q3 2025 holders
53
Holder diff
-14
| Investor | Q4 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.